Bibliometric analysis of the 100 most cited articles on cervical cancer radiotherapy
Conclusion: To the best of our knowledge, this is the first report and analysis of the most cited articles on cervical cancer radiotherapy. This bibliographic study presents the history of technological development in external radiation therapy and brachytherapy. Brachytherapy is an indispensable part of radiotherapy for cervical cancer. The International Journal of Radiation Oncology Biology Physics is the journal with the most publications related to cervical cancer radiotherapy.
Regular audits are a key component to a quality radiation treatment program. In an effort to understand current practice and plan for future state we performed an outcomes audit of our locally advanced cervix cancer patients treated with concurrent chemotherapy, external beam radiation therapy and brachytherapy. Our objective was to determine treatment outcomes and late toxicity
SCNEC is a rare disease with aggressive clinical behavior. The findings indicates that radical surgery should be suggested for early ‐stage SCNEC and combining radiation therapy with brachytherapy should be suitable for patients with advanced stage. AbstractObjectiveWe aimed to assess the impact of the treatment modality on the outcome of small cell neuroendocrine cervical carcinoma (SCNEC) using the Surveillance Epidemiology and End Results (SEER) database.MethodsPatients from the SEER program between 1981 and 2014 were identified. Significant factors for cancer ‐specific survival (CSS) and overall survival (OS) were ...
Conclusions: Unlike past results, gemcitabine and cisplatin appear to be tolerable, efficient and feasible when combined with conformal radiotherapy.
(Medical College of Georgia at Augusta University) The sugar coating on cancer cells helps them thrive, and a new study indicates patients with cervical cancer who make antibodies to those sugars appear to do better when they also receive internal radiation therapy.
(American Society for Radiation Oncology) A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline--ASTRO's first for cervical cancer--outlines indications and best practices for external beam radiation therapy and brachytherapy in the postoperative and definitive settings. Recommendations also address other treatments including chemotherapy and surgery when used in combination with radiation. The guideline is published online in Practical Radiation Oncology.
According to international recommendations by GEC-ESTRO GYN working group , combined radiation therapy is the most effective treatment for locally advanced cervical cancer (LACC). Classical combined radiotherapy includes two sequential stages: external beam radiotherapy (EBRT) and brachytherapy (BT) . EBRT is used for irradiation of the tumour itself and the lymph nodes to total dose values up to 50Gy. BT is used as a boost for irradiation of the tumour up to EQD2 doses as high as 90Gy. The golden standard of modern combined radiotherapy includes EBRT followed by image-guided adaptive BT.
The standard treatment for locally advanced cervical cancer is external beam radiation therapy and concurrent cisplatin followed by brachytherapy. Traditionally, 2-dimensional brachytherapy (2DBT) or computed tomography guided brachytherapy (CTgBT) has been used, but magnetic resonance guided brachytherapy (MRgBT) improves clinical outcomes and has become the new standard of care. This cost-utility analysis was undertaken to compare MRgBT to CTgBT and 2DBT.
Abstract Brachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law. High-dose-rate brachytherapy enables three-dimensional image guidance, and currently, tumor dose as well as doses of the surrounding normal structures can be evaluated accurately. High-dose-rate brachytherapy is the utmost precision radiation therapy even surpassing carbon ion therapy. Biological disadvantages of high-dose rate have been overcome by th...
We applaud the University of Texas Southwestern Department of Radiation Oncology for conducting “A phase II trial of stereotactic ablative radiotherapy as a boost for locally advanced cervical cancer,” a necessary prospective study on definitive dose delivery for patients unable to undergo brachytherapy.1 The involved trialists were undoubtedly deliberate and meticulous in its design and e xecution, akin to their groundbreaking work with lung stereotactic body radiation therapy (SBRT). Although these results unfortunately showed high rates of rectal toxicity, the data does not indicate a failure of SBRT, but ra...
Conclusions: Our findings suggest that IMRT may represent a viable alternative in delivering the boost in patients diagnosed with gynaecological cancer not amenable to ICBRT. PMID: 32010217 [PubMed]